本帖最后由 老马 于 2013-3-13 13:43 编辑 ' @' W0 I5 ]: p$ u0 M
& |1 \" C+ `# i
健择（吉西他滨）+顺铂+阿瓦斯汀+ U4 {6 c# {; T
Gemzar +Cisplatin + Avastin2 P' x) p% \1 T& I8 r/ [! w
http://annonc.oxfordjournals.org/content/21/9/1804.full: n, L# l+ P/ C0 z9 V& P
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) % m5 b! z. z& H3 P, N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 @* w- i9 _$ ]' b( f0 L* @
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' ^( m2 Z8 s& z: g
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 532)
9 t$ b/ z) w+ R华为网盘附件：5 U, E& f0 h2 p8 k
【华为网盘】ava.JPG; F d; M; |' l! Q- {" r7 k
|
显身卡
